Kerecis is pioneering the use of fish skin and fatty acids in the globally expanding cellular-therapy and regenerative-medicine markets. The fatty-acid-rich products from the company’s patented technologies protect the body’s own tissues and enable the body to regenerate tissues.
Developed and manufactured in Isafjordur, Iceland, Kerecis medical products are authorized for sale in Europe, the United States. and several other jurisdictions for human-tissue repair. Thousands of patients are treated annually with our technology. And we are broadening our product line to address many more types of soft-tissue damage.
We are a fast-growing company rooted in science and environmental sustainability. Today more than 200 employees are led by an experienced management team, board of directors and scientific advisory board. We have regional headquarters in the United States, Germany and Iceland.
The company’s mission is to become a world leader in regenerating damaged human tissues by sustainably harnessing nature’s own remedies. Its vision is to extend human life by supporting the body’s own ability to protect and regenerate tissues.
The Kerecis operational headquarters are located in Arlington, Virginia, near Washington, D.C. Research & Development is based in Reykjavik, Iceland, with European and Asian sales run from the company’s office in Germany. The Kerecis products are manufactured in its own manufacturing facility in Isafjordur, Iceland.
Kerecis sells its products through a mixture of direct sales in the United States and employs agents and distributors worldwide. The products are sold to hospitals, healthcare facilities, physicians and consumers.
On July 7 2023 Coloplast acquired Kerecis.
Kerecis products utilize multiple patented fatty-acid technologies to protect and regenerate tissue. Our core technology is the Kerecis Fish Skin. Kerecis products categorize as medical devices and go through a rigorous process to be approved and commercialized in countries around the world. The Kerecis technology is patented in the United States and in more than 40 other countries.
Kerecis participates in several projects funded by governments around the world including the United States (Department of Defense or the DoD) and the EU. The company is committed to developing better remedies for injured American servicemen and women.
Kerecis is actively seeking future licensing and distribution partners, while focusing on product development, intellectual property protection and clinical trials. Ideal potential technology licensees will have the ability to launch these proprietary devices in markets around the world.
The Kerecis Fish Skin technology was invented by the company’s founder and CEO, Fertram Sigurjonsson. The company started commercial operations in 2013 and established its U.S. headquarters in 2016.
In 2019, the company acquired the Swiss life-science company Phytoceuticals AG, which has since changed its name to Kerecis AG.